EMA accepts application for pegfilgrastim biosimilar from USV

Biosimilars/News | Posted 26/01/2018 post-comment2 Post your comment

India-based biologicals specialist USV Biologics (USV) announced on 7 December 2017 that the application for approval for its proposed pegfilgrastim biosimilar has been accepted by the European Medicines Agency (EMA).

24 AA011041

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue filgrastim. It serves to stimulate the level of white blood cells (neutrophils). Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy.

Europe is expected to be a crowded market for pegfilgrastim biosimilars. This acceptance follows another announcement by India-based biologicals specialist Biocon and US-based partner Mylan that their pegfilgrastim biosimilar (MYL 1401H) was accepted for review by EMA [1]. Spanish-based Cinfa Biotech and US-based Coherus also submitted applications for approval of pegfilgrastim biosimilars to EMA in October 2017 and November 2016, respectively [2, 3]. Sandoz also resubmitted its application to EMA for approval in October 2017 [4], and Stada Arzneimittel/Gedeon Richter submitted an application to EMA for approval back in December 2015 [5].

USV’s product is a proposed biosimilar to Amgen's Neulasta.

USV has a pipeline of seven biosimilar (products produced by recombinant biotechnology in E.coli) at various stages of development, from lab scale, clinical to market authorization.

To date, EMA has not yet approved a pegfilgrastim biosimilar.

Related article
Biosimilars of pegfilgrastim

References
1. GaBI Online - Generics and Biosimilars Initiative. EMA accepts applications for pegfilgrastim and trastuzumab biosimilars from Biocon/Mylan [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jan 26]. Available from: www.gabionline.net/Biosimilars/News/EMA-accepts-applications-for-pegfilgrastim-and-trastuzumab-biosimilars-from-Biocon-Mylan
2. GaBI Online - Generics and Biosimilars Initiative. More positive phase I results for Coherus pegfilgrastim biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jan 26]. Available from: www.gabionline.net/Biosimilars/Research/More-positive-phase-I-results-for-Coherus-pegfilgrastim-biosimilar
3. GaBI Online - Generics and Biosimilars Initiative. ‘Similar biologics’ approved and marketed in India [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jan 26]. Available from: www.gabionline.net/Biosimilars/General/Similar-biologics-approved-and-marketed-in-India
4. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of trastuzumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jan 26]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-trastuzumab
5. Derbyshire M. Patent expiry dates for biologicals: 2016 update. Generics and Biosimilars Initiative Journal (GaBI Journal). 2017;6(1):27-30. doi:10.5639/gabij.2017.0601.006

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Source: Livemint, USV

comment icon Comments (2)
Post your comment
Posted 29/01/2018 by Louis B, GaBI Online Editorial Office
Response to ‘EMA accepts application for pegfilgrastim biosimilar from USV’

Dear Ms Superna Thakur,
Thank you for your valuable comments and insight received on 29 January 2018, we have followed-up on your suggestion and researched the issue further. As a result, we have updated article ‘EMA accepts application for pegfilgrastim biosimilar from USV’ with the current information.
We very much appreciate your kind feedback. Thank you for your interest in GaBI, and please continue with your valuable comments to GaBI Online. Best Regards, Louis

Posted 29/01/2018 by Ms. Superna Thakur
EMA accepts application for pegfilgrastim biosimilar from USV

Dear GaBi team

Please note that USV Pegfilgrastim is not a proposed biosimilar of Roche's Herceptin (Transtuzumab). It is a proposed biosimilar to Amgen's Neulasta.

Appreciate your effort of keeping us updated of all the happenings and development in biosimilar world.


Thank you,
Superna Thakur
Regulatory Affairs (Biosimilars)
Mumbai, India

Related content
Clinical trials for aflibercept biosimilars
Clinical trial PainSA V21F04
Biosimilars/News Posted 04/06/2021
Australia approves adalimumab biosimilar Abrilada
Adalimumab 2 V14A10
Biosimilars/News Posted 21/05/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010